Mind Medicine (MindMed) Inc. (MNMD) Research

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering new treatments for various brain health conditions, encompassing psychiatric disorders, addiction, pain, and neurological ailments. Among its key pipeline assets is MM-120, currently undergoing Phase 2 clinical trials. This candidate is being investigated for its potential in addressing generalized anxiety disorder, attention deficit hyperactivity disorder (ADHD), and chronic pain. Furthermore, MM-110, an a3ß4 nicotinic cholinergic receptor antagonist, has successfully completed Phase 1 studies for managing opioid withdrawal. The company's portfolio also includes MM-402, an R-enantiomer of 3,4-methylenedioxymethamphetamine, aimed at treating the core symptoms associated with autism spectrum disorder. Its corporate headquarters are situated in Vancouver, Canada.

Market snapshot

Symbol
MNMD
Price
$20.69
Day change
+0.44%
Market cap
$2.7B
P/E ratio
-11.21x
52-week range
4.7-21.08
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$20.00

Peer companies

  • AnaptysBio, Inc. (ANAB)
  • BridgeBio Oncology Therapeutics Inc. (BBOT)
  • Fortrea Holdings Inc. (FTRE)
  • Kodiak Sciences Inc. (KOD)
  • Nurix Therapeutics, Inc. (NRIX)
  • Rezolute, Inc. (RZLT)
  • Savara Inc. (SVRA)
  • Tango Therapeutics, Inc. (TNGX)

Recent insider activity

  • Makes Brigid — A-Award (361680 shares) on 2022-06-01
  • Makes Brigid — A-Award (100308 shares) on 2022-06-01
  • Makes Brigid — A-Award (64656 shares) on 2022-06-01
  • Greenway Schond L. — A-Award (1650000 shares) on 2022-05-23
  • Greenway Schond L. — A-Award (1270000 shares) on 2022-05-23

Open Mind Medicine (MindMed) Inc. (MNMD) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.